利用针对新生血管性眼病优化的双特异性CrossMAb靶向关键血管生成途径。
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
作者信息
Regula Jörg T, Lundh von Leithner Peter, Foxton Richard, Barathi Veluchamy A, Gemmy Cheung Chui Ming, Bo Tun Sai Bo, Wey Yeo Sia, Iwata Daiju, Dostalek Miroslav, Moelleken Jörg, Stubenrauch Kay G, Nogoceke Everson, Widmer Gabriella, Strassburger Pamela, Koss Michael J, Klein Christian, Shima David T, Hartmann Guido
出版信息
EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895.
Abstract
[Image: see text]
摘要
[图像：见正文]
相似文献
1
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.利用针对新生血管性眼病优化的双特异性CrossMAb靶向关键血管生成途径。
EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895.
2
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.利用针对新生血管性眼病优化的双特异性CrossMAb靶向关键血管生成途径。
EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201910666.
3
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.血管生成素-2（Ang-2）-血管内皮生长因子-A（VEGF-A）双特异性单克隆抗体（CrossMab），一种新型的同时阻断 VEGF-A 和 Ang-2 功能的人源 IgG1 抗体，具有强大的抗肿瘤、抗血管生成和抗转移疗效。
Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4.
4
Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.血管生成素-2-血管内皮生长因子-A双特异性抗体在肾细胞癌中的作用
Cancer Invest. 2015;33(8):378-86. doi: 10.3109/07357907.2015.1047505. Epub 2015 Jun 26.
5
An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab.一种免疫去除程序可在使用双特异性抗血管生成素-2/血管内皮生长因子（Ang2/VEGF）双特异性交叉单克隆抗体（CrossMab）进行抗癌治疗期间，提高人血浆样本中游离血管生成素-2的检测水平。
J Pharm Biomed Anal. 2015 Jan;102:459-67. doi: 10.1016/j.jpba.2014.10.005. Epub 2014 Oct 14.
6
Bispecific antibody derivatives based on full-length IgG formats.基于全长IgG形式的双特异性抗体衍生物。
Methods Mol Biol. 2012;901:247-63. doi: 10.1007/978-1-61779-931-0_16.
7
SPR-based assays enable the full functional analysis of bispecific molecules.基于表面等离子体共振（SPR）的检测方法能够对双特异性分子进行全面的功能分析。
J Pharm Biomed Anal. 2017 Jan 5;132:141-147. doi: 10.1016/j.jpba.2016.09.028. Epub 2016 Sep 26.
8
Complement involvement in neovascular ocular diseases.补体系统在新生血管性眼病中的作用。
Adv Exp Med Biol. 2012;946:161-83. doi: 10.1007/978-1-4614-0106-3_10.
9
Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development.靶向血管内皮生长因子治疗眼部新生血管：有哪些新进展？：关于当前治疗方法及正在研发的基于寡核苷酸干预措施的全面综述
Pharmacol Res. 2016 Jan;103:253-69. doi: 10.1016/j.phrs.2015.11.027. Epub 2015 Dec 8.
10
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.靶向血管内皮生长因子-A（VEGF-A）和血管生成素-2的四价双特异性抗体（TAvi6）的抗肿瘤、抗血管生成和抗转移疗效
MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.
引用本文的文献
1
Analysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD.玻璃体内注射法西单抗治疗顽固性新生血管性年龄相关性黄斑变性三个月后定量光学相干断层扫描（OCT）和扫频光学相干断层血管造影（SS-OCTA）指标分析
Eye (Lond). 2025 May;39(7):1337-1343. doi: 10.1038/s41433-024-03583-3. Epub 2025 Jan 25.
2
Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy.超越血管内皮生长因子：糖尿病视网膜病变中的血管生成素-Tie信号通路
J Clin Med. 2024 May 9;13(10):2778. doi: 10.3390/jcm13102778.
3
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.针对脉络膜新生血管的抗血管内皮生长因子治疗策略在新生血管性年龄相关性黄斑变性中的应用。
Biomolecules. 2024 Feb 21;14(3):252. doi: 10.3390/biom14030252.
4
A pivotal decade for bispecific antibodies?双特异性抗体的关键十年？
MAbs. 2024 Jan-Dec;16(1):2321635. doi: 10.1080/19420862.2024.2321635. Epub 2024 Mar 11.
5
Angiopoietins as Potential Targets in Management of Retinal Disease.血管生成素作为视网膜疾病治疗的潜在靶点。
Clin Ophthalmol. 2021 Sep 4;15:3747-3755. doi: 10.2147/OPTH.S231801. eCollection 2021.
6
Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study.抗血管内皮生长因子 A/血管生成素 2 联合治疗抑制眼部病理性血管生成：一项复制研究。
EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201910362.
7
Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly.具有带电残基交换的可变重链-可变轻链结构域和Fab臂交叉单克隆抗体，以促进正确的轻链组装。
Protein Eng Des Sel. 2018 Jul 1;31(7-8):289-299. doi: 10.1093/protein/gzy021.
Zotero 插件